Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Wall Street Zen upgrades DiaMedica Therapeutics from “Sell” to “Hold” rating.
  • Analysts maintain consensus “Buy” rating with average target price of USD 12.33.
  • Company reported Q2 EPS of (USD 0.18), matching analyst expectations.

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has received an upgrade from Wall Street Zen, moving from a “Sell” rating to a “Hold” rating in its latest research note issued Wednesday. This change reflects a more neutral stance on the company’s near-term performance after previously negative sentiment.

The stock has been the subject of several other research reports in recent months. HC Wainwright reaffirmed its “Buy” rating and set a target price of USD 12.00 on August 15th. Lake Street Capital raised its target price from USD 11.00 to USD 14.00 while maintaining a “Buy” rating in July, and Craig Hallum increased its price objective from USD 8.00 to USD 11.00 with a “Buy” rating as well.

In total, three analysts currently rate DiaMedica Therapeutics as a “Buy”, according to MarketBeat data, resulting in a consensus rating of “Buy” and a consensus price target of USD 12.33.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases, particularly acute ischemic stroke. Its lead drug candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein. DM199 is currently in Phase II/III clinical trials for stroke treatment and in Phase II trials for cardio-renal disease, representing a potential multi-indication therapeutic pipeline.

Financially, the company reported a second-quarter earnings loss of USD 0.18 per share, in line with consensus expectations.